AbbVie Inc.

PatientFi® Enters Partnership with Allergan Aesthetics to Provide Natrelle® Breast Implant Financing Options to Patients

Retrieved on: 
Monday, February 8, 2021
Technology, Cosmetics, Retail, Health, Finance, Consumer, Other Health, Surgery, Professional services, Practice Management, Marketing, Software, Communications, Women, Breast surgery, Medicine, Companies, Clinical medicine, Breast implant, Breast augmentation, Allergan, AbbVie Inc., Breast cancer, PatientFi, Allergan Aesthetics, AbbVie

PatientFi, a point of sale financing company that helps make elective procedures more affordable for patients, announces it has entered into a co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in breast augmentation with Natrelle Breast Implants.

Key Points: 
  • PatientFi, a point of sale financing company that helps make elective procedures more affordable for patients, announces it has entered into a co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in breast augmentation with Natrelle Breast Implants.
  • By way of this partnership, Natrelle breast augmentation patients will be able to finance their surgery via a monthly payment plan.
  • We are thrilled to be partnering with Allergan Aesthetics to help provide a new approach to patient financing for women seeking Natrelle breast augmentation.
  • Removing the barrier of affordability for patients with our unique financing alternative creates a 'win-win' for medical providers and patients.

CollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft Tissue Filler Products

Retrieved on: 
Monday, February 8, 2021
Companies, Allergan, Health, AbbVie Inc., Dermis, Collagen, Pharmacology

REHOVOT, Israel, Feb. 8, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced it has entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company.

Key Points: 
  • REHOVOT, Israel, Feb. 8, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced it has entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company.
  • CollPlanthasgrantedAllergan Aesthetics worldwide exclusivity to use itsplant-derived recombinant human collagen (rhCollagen)in combination with Allergan Aesthetics' proprietary technologies, for the production and commercialization of dermal and soft tissue fillers.
  • In addition, CollPlant is eligible to receive royalty payments and a fee for the manufacture and supply of rhCollagen to Allergan Aesthetics.
  • Yehiel Tal, Chief Executive Officer of CollPlant, stated, "We are very pleased to formalize this collaboration with Allergan Aesthetics, the worldwide leader in dermal and soft tissue fillers.

Worldwide Dry Eye Disease Industry to 2025 - Featuring AbbVie, Alcon & VISUfarma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 16, 2020
Health, Optical, Medicine, RTT, Ophthalmology, Companies, Blindness, Allergan, Cataract, ICD-10 Chapter VII: Diseases of the eye, adnexa, AbbVie Inc., Disease

These are widely available and rapidly relieve the symptoms and signs of moderate and severe dry eye diseases.

Key Points: 
  • These are widely available and rapidly relieve the symptoms and signs of moderate and severe dry eye diseases.
  • These drugs are highly useful in short-term efficacy, and thus, are prescribed mostly for acute cases of dry eye diseases.
  • However, the long-term usage of these drugs has major side effects, such as intraocular pressure elevation and cataract progression.
  • Two of the major companies established in this segment are Bausch Health and AbbVie Inc (Allergan Plc).

Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma

Retrieved on: 
Tuesday, July 7, 2020
Branches of biology, Biology, Cell biology, Cell signaling, Orphan drugs, Brain tumor, Chloroarenes, Protein kinase inhibitors, Medulloblastoma, Silmitasertib, Priority review, AbbVie Inc.

Food and Drug Administration(FDA) granted Rare Pediatric Disease (RPD) Designation for its drug Silmitasertib, a Casein Kinase 2 (CK2) inhibitor,being developed as a treatment for recurrent sonic hedgehog (SHH) medulloblastoma.

Key Points: 
  • Food and Drug Administration(FDA) granted Rare Pediatric Disease (RPD) Designation for its drug Silmitasertib, a Casein Kinase 2 (CK2) inhibitor,being developed as a treatment for recurrent sonic hedgehog (SHH) medulloblastoma.
  • With the RPD designation, Senhwa Biosciences is eligible for a Priority Review Voucher (PRV) which can be used for a subsequent marketing application, and may be sold or transferred.
  • In August 2015, AbbVie bought a PRV from United Therapeutics Corp for $350 million which allowed AbbVie to accelerate one of its drug's FDA review process.
  • Treatment for medulloblastoma usually includes surgery, followed by radiation or chemotherapy, or both.Currently there is no targeted drug available.

AbbVie to Host Second-Quarter 2020 Earnings Conference Call

Retrieved on: 
Tuesday, July 7, 2020
AbbVie Inc., Companies, Illinois

NORTH CHICAGO, Ill., July 7, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2020 financial results on Friday, July 31, 2020, before the market opens.

Key Points: 
  • NORTH CHICAGO, Ill., July 7, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2020 financial results on Friday, July 31, 2020, before the market opens.
  • AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time.
  • AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.
  • For more information about AbbVie, please visit us at www.abbvie.com .

AbbVie 2020: Company Background, Recent Earnings Review, Company Forecast, Company Profile and Clinical Trial Overview

Retrieved on: 
Tuesday, July 7, 2020
Chemical compounds, Drugs, Organic compounds, Breakthrough therapy, Monoclonal antibodies, Biotechnology, Adalimumab, Immunosuppressants, RTT, AbbVie Inc., Biosimilar, Allergan

DUBLIN, July 7, 2020 /PRNewswire/ -- The "AbbVie" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 7, 2020 /PRNewswire/ -- The "AbbVie" company profile has been added to ResearchAndMarkets.com's offering.
  • This report explores AbbVie's prescription pharmaceutical performance and outlook over 2019-2029.
  • Declines in AbbVie's flagship product Humira due to biosimilar competition will be offset by the company's robust portfolio of launch drugs.
  • [1] Biosimilar launches in Europe and other international markets have negatively impacted Humira's growth, but the brand could grow in 2020 and should have revenue stability until US biosimilar launches in 2023
    [2] AbbVie will see tremendous growth from Imbruvica, Skyrizi, Rinvoq, and Venclexta
    [3] Acquisition of Allergan, poised to close in 2020, will further diversify AbbVie's revenues
    Skyrizi forecast adjusted higher due to robust launch in the US; international forecast adjusted lower due to slower launch in the five major EU markets and Rest of World
    Imbruvica forecast adjusted higher globally due to recent inflection in market share in first-line CLL.

Reata Announces Promotion and New Hires For Key Leadership Roles

Retrieved on: 
Tuesday, July 7, 2020
Companies, Reata Pharmaceuticals, AbbVie Inc., Economy of the United States

PLANO, Texas, July 07, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, or we), a clinical-stage biopharmaceutical company, today announced the expansion of its leadership team and the appointment of several experienced industry leaders to key management roles.

Key Points: 
  • PLANO, Texas, July 07, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, or we), a clinical-stage biopharmaceutical company, today announced the expansion of its leadership team and the appointment of several experienced industry leaders to key management roles.
  • In addition, Reata welcomes the following new hiresall of whom have significant industry and commercial experienceto key leadership positions within the Company:
    Seemi Khan, MD has been named Chief Medical Officer at Reata.
  • Her prior industry experience includes leadership roles at Mitsubishi Tanabe, Quark Pharma, and AbbVie.
  • "We are delighted to make these key additions to our leadership team," said Warren Huff, Reatas Chief Executive Officer and President.

Protein Therapeutics Market 2020-2024 | Increased Demand for mAbs to Boost Growth | Technavio

Retrieved on: 
Wednesday, July 1, 2020
General Health, Pharmaceutical, Health, Companies, Life sciences, Pfizer, AbbVie Inc., Sanofi, AstraZeneca, Monoclonal antibodies

Our protein therapeutics market report covers the following areas:

Key Points: 
  • Our protein therapeutics market report covers the following areas:
    This study identifies the development of novel therapies using innovative technologies as one of the prime reasons driving the protein therapeutics market growth during the next few years.
  • We provide a detailed analysis of vendors operating in the protein therapeutics market, including some of the vendors such as AbbVie Inc., Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Novo Nordisk AS, Pfizer Inc., and Sanofi.
  • Backed with competitive intelligence and benchmarking, our research reports on the protein therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Eli Lilly's Reyvow Struggles to Gain Ground in the Acute Segment of the US Migraine Market, Overshadowed by AbbVie's Ubrelvy and Biohaven's Nurtec ODT, According to Spherix Global Insights

Retrieved on: 
Tuesday, June 30, 2020
Articles, Health informatics, Technology, Migraine, Telehealth, AbbVie Inc., Companies

However, only AbbVie and Eli Lilly offer multiple options for both the acute and preventive treatment of migraines.

Key Points: 
  • However, only AbbVie and Eli Lilly offer multiple options for both the acute and preventive treatment of migraines.
  • In addition, the Ubrelvy prescriber base is now twice that of Reyvow, although both brands were launched in January.
  • While Ubrelvy lags behind Nurtec ODT on telemedicine platform awareness and use, many recent Ubrelvy prescriptions were prescribed following remote evaluation.
  • Similarly, not all is rosy for AbbVie and Ubrelvy, with Biohaven's recently launched Nurtec ODT proving to be a formidable adversary.

Psychedelic Drugs Market Projected to Reach $6.85 Billion by 2027

Retrieved on: 
Wednesday, June 24, 2020
Companies, AbbVie Inc., Allergan, Master of Medicine, Psychedelic drug, Psychedelic music, Health

NEW YORK, June 24, 2020 /PRNewswire/ -- The psychedelic drugs market is projected to grow at a CAGR of 16.3% over the next eight years to reach $6.8 5 billion by 2027 , according to Data Bridge Market Research.

Key Points: 
  • NEW YORK, June 24, 2020 /PRNewswire/ -- The psychedelic drugs market is projected to grow at a CAGR of 16.3% over the next eight years to reach $6.8 5 billion by 2027 , according to Data Bridge Market Research.
  • Meanwhile, Mota Ventures Corp. (OTCPK:PEMTF) (CSE:MOTA)is entering the psychedelic drug market through the acquisition of European psychedelic medicine company Verrian Ontario Ltd.
  • Even Big Pharma giant AbbVie Inc. (NYSE:ABBV)recently gained a stake in the psychedelic drugs market through the acquisition of Allergan PLC .
  • However, it appears that pure-play psychedelic medicine company Mind Medicine (MindMed) Inc. (NEO:MMED) (OTCQB:MMEDF) is a front-runner with multiple novel therapies moving through clinical trials.